CR10912A - Preparacion framaceutica para reducir la endometriosis - Google Patents

Preparacion framaceutica para reducir la endometriosis

Info

Publication number
CR10912A
CR10912A CR10912A CR10912A CR10912A CR 10912 A CR10912 A CR 10912A CR 10912 A CR10912 A CR 10912A CR 10912 A CR10912 A CR 10912A CR 10912 A CR10912 A CR 10912A
Authority
CR
Costa Rica
Prior art keywords
framaceutical
preparation
endometriosis
reduce
reduce endometriosis
Prior art date
Application number
CR10912A
Other languages
English (en)
Inventor
Christian Seitz
Annemarie Wasserfall
Holger Zimmermann
Original Assignee
Bayer Schering Parma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Parma Ag filed Critical Bayer Schering Parma Ag
Publication of CR10912A publication Critical patent/CR10912A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion farmaceutica para el tratamiento de endometrisis sin reducir la densidad osea contiene un gestageno con eficacia antiandrogenica, con preferencia 17a-cianometil-17B-hidroxiestra-4,9-dien-3-ona (dienogest), acetato de ciproterona o acetato de cloromadinona en una dosis diaria que es como maximo el doble de la dosis inhibidora de la ovulacion, junto con uno o varios excipientes/portadores farmaceuticamente aceptables.
CR10912A 2007-03-01 2009-07-03 Preparacion framaceutica para reducir la endometriosis CR10912A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07004202A EP1977752A1 (de) 2007-03-01 2007-03-01 Pharmazeutische Zubereitung zur Verminderung der Endometriose

Publications (1)

Publication Number Publication Date
CR10912A true CR10912A (es) 2009-08-13

Family

ID=38045772

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10912A CR10912A (es) 2007-03-01 2009-07-03 Preparacion framaceutica para reducir la endometriosis

Country Status (18)

Country Link
EP (2) EP1977752A1 (es)
JP (1) JP2010520159A (es)
KR (1) KR20090119829A (es)
CN (1) CN101583364A (es)
AU (1) AU2008221012A1 (es)
BR (1) BRPI0806598A2 (es)
CA (1) CA2673936A1 (es)
CO (1) CO6190606A2 (es)
CR (1) CR10912A (es)
DO (1) DOP2009000171A (es)
EA (1) EA200900829A1 (es)
EC (1) ECSP099482A (es)
MA (1) MA31162B1 (es)
MX (1) MX2009007259A (es)
NZ (1) NZ577761A (es)
SV (1) SV2009003324A (es)
TN (1) TN2009000263A1 (es)
WO (1) WO2008104342A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874806A (zh) * 2009-04-29 2010-11-03 北京本草天源药物研究院 一种地诺孕素固体制剂
CN102670519B (zh) * 2011-03-16 2014-06-11 重庆莱美药业股份有限公司 一种可快速溶出的地诺孕素口服制剂及其制备方法
CN103304619B (zh) * 2013-06-08 2015-12-02 西藏海思科药业集团股份有限公司 一种地诺孕素化合物
TW202523334A (zh) * 2023-12-13 2025-06-16 大陸商長春金賽藥業有限責任公司 原位皮下植入的女性激素調節組合物及其製備方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026679A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
EP1655031A1 (de) * 2004-10-08 2006-05-10 Schering AG Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung

Also Published As

Publication number Publication date
EP1977752A1 (de) 2008-10-08
CA2673936A1 (en) 2008-09-04
CN101583364A (zh) 2009-11-18
MX2009007259A (es) 2009-07-10
DOP2009000171A (es) 2009-08-31
CO6190606A2 (es) 2010-08-19
SV2009003324A (es) 2009-10-02
ECSP099482A (es) 2009-08-28
EA200900829A1 (ru) 2010-02-26
TN2009000263A1 (en) 2010-10-18
MA31162B1 (fr) 2010-02-01
JP2010520159A (ja) 2010-06-10
KR20090119829A (ko) 2009-11-20
AU2008221012A1 (en) 2008-09-04
WO2008104342A1 (de) 2008-09-04
EP2059248A1 (de) 2009-05-20
NZ577761A (en) 2012-03-30
BRPI0806598A2 (pt) 2014-05-06

Similar Documents

Publication Publication Date Title
NO20091954L (no) Anvendelse av ostradiolvalerat eller 17ß-ostradil i kombinasjon med dienogest for oral terapi for opprettholdelse og/eller okning av kvinnelig libido
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
UY33343A (es) Formas de dosificación sólidas orales con dosis muy bajas para la hrt
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
JP2016053040A5 (es)
NZ594022A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
MY160768A (en) Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease
ES2693085T1 (es) Uso de estriol en bajas dosis
UY32260A (es) Forma de dosificación farmacéutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o diuretico
UY30461A1 (es) Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas.
CR10912A (es) Preparacion framaceutica para reducir la endometriosis
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.
AR080541A1 (es) Tratamiento para la endometriosis
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
CR9324A (es) Preparación farmacéutica para la anticoncepción oral
CU20090116A7 (es) Preparación farmacéutica para reducir la endometriosis
AR053546A1 (es) Forma farmacologica peroral solida para la anticoncepcion
AR116592A1 (es) Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
DOP2007000122A (es) Forma farmacologica peroral para anticoncepcion
PA8793901A1 (es) Uso de gestágenos en combinación con (6s)-5-metiltetrahidrofolato para la terapia la endometriosis con simultánea reducción de los efectos colaterales terapéuticos, así como reducción del riesgo de malformaciones congénitas al comenzar un embarazo
CU20110070A6 (es) Método para tratar la endometriosis sin disminuir la densidad ósea
PE20091020A1 (es) Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa
UY29378A1 (es) Preparación farmaceutica para la anticoncepción oral
CU20090062A7 (es) Uso de valerato de estradiol o 17beta-estradiol en combinación con dienogest en una terapia oral para mantener y/o incrementar la líbido femenina